- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05292287
Remote Maintenance Cardiac Rehabilitation (MAINTAIN)
August 19, 2024 updated by: Francesca Denton, Coventry University
Remote Maintenance Cardiac Rehabilitation: a Randomised Feasibility Study
The investigators would like to test the feasibility of a remotely prescribed and monitored exercise program in people with coronary heart disease, using a wearable activity device and text message support, compared to usual care after completing cardiac rehabilitation.
One group will use a Polar Ignite watch to guide them through exercise sessions at home and will receive text message feedback.
The other group will be asked to continue their routine as usual.
Assessments of both groups will happen after the completion of cardiac rehabilitation and at three follow-up time points of three, six, and twelve months.
The aim of these treatments is to see if the investigators can help people to maintain their exercise adherence and coronary heart disease risk factor management after completing cardiac rehabilitation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Following the completion of centre-based cardiac rehabilitation (CR), lifetime adoption of physical activity (PA) and adherence to exercise is often poor.
Wearable activity monitors may be a tool to remotely prescribe and monitor PA and exercise to promote long term behaviour change.
This research aims to assess the feasibility of conducting a randomised controlled trial (RCT) testing a remotely prescribed and monitored long-term maintenance exercise programme in cardiac rehabilitation graduates with coronary heart disease (CHD).
30 participants with CHD will be recruited to a 12-month feasibility RCT and randomised into 2 arms: 1) a home-based watch intervention group and 2) a best practice usual care control group.
The intervention group will receive an initial exercise consultation, personalised exercise prescription delivered via a Polar Ignite watch, and monitoring via check-ins and feedback text-message support with a clinical exercise physiologist.
The control group will receive no intervention.
All participants will undergo assessment at baseline (following the completion of CR) and at 3 follow up time points including 3-, 6- and 12-months.
The primary outcome will be to assess feasibility and other process-related outcomes.
The secondary outcomes will include exercise capacity, physical activity and sedentary behaviour, exercise time, cardiovascular disease risk, quality of life, depression, anxiety, self-efficacy, patient activation, health utility, health and social care resource use, cost, and adverse and serious adverse events.
Semi-structured interviews will be conducted at 3-, 6-, and 12-months post-randomisation to explore the views, perceptions, acceptability, and experiences of the remotely prescribed and monitored exercise intervention and trial procedures.
Participants who drop out or choose not to participate will be offered a semi-structured interview or a questionnaire, respectively, to understand feasibility.
Overall, there is a need to support people post-CR to remotely maintain PA and exercise behaviour for secondary prevention of CHD particularly during the era of government-enforced restrictions or lockdowns due to the COVID-19 pandemic.
The MAINTAIN study will assess the feasibility of longer-term remote prescription and monitoring of maintenance exercise following CR using a wearable activity monitor and text message support compared to best practice usual care for people diagnosed with CHD.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
West Midlands
-
Coventry, West Midlands, United Kingdom, CV1 3LN
- Atrium Health Limited
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosed coronary heart disease.
- Completed community cardiac rehabilitation.
- Clinically stable (symptoms and medication).
- Men and women aged over 18.
- Access to smartphone with Bluetooth capacity or a computer/laptop.
- Able to provide informed consent.
Exclusion Criteria:
- Absolute contraindications to exercise as per international clinical guidelines.
- Any serious mental health/cognitive issue that will prevent engagement with study procedures or increase the risk of exercise complications.
- Diagnosed atrial fibrillation or other arrhythmia preventing accurate heart rate measurement.
- Allergy to watch materials.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Home-based Watch Intervention
The home-based watch group will receive an exercise consultation with an exercise physiologist followed by check-in sessions at 1-month, 3-months, 6-months, and 12-months post-randomisation to set and review exercise and physical activity goals.
They will wear a Polar Ignite wearable activity monitor which will help to monitor and guide their exercise sessions.
Text-message feedback will be provided by an exercise physiologist based on information gathered from exercise sessions recorded on the watch by the participant.
|
A wearable activity monitor capable of monitoring outcomes relating to physical activity sedentary time, heart rate, and sleep quality.
The watch synchronises to a corresponding mobile app called Polar Flow- Sync and Analyze or to the Polar FlowSync data transfer software on a computer.
|
|
No Intervention: Best Practice Usual Care Control
No intervention will be administered.
Best practice usual care and activity.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intervention feasibility assessed via recruitment rate.
Time Frame: Will be evaluated after the 12-month follow up assessment
|
The investigators will complete enrolment logs to record the number of people who enrol in the study.
|
Will be evaluated after the 12-month follow up assessment
|
|
Intervention feasibility assessed via number of screened patients.
Time Frame: Will be evaluated after the 12-month follow up assessment
|
The investigators will complete screening logs to record the number of eligible participants.
|
Will be evaluated after the 12-month follow up assessment
|
|
Intervention feasibility assessed via number of patients randomised.
Time Frame: Will be evaluated after the 12-month follow up assessment
|
The investigators will complete randomisation logs to record the number of participants randomised to both groups.
|
Will be evaluated after the 12-month follow up assessment
|
|
Intervention feasibility assessed via number of patients retained in the study.
Time Frame: Will be evaluated after the 12-month follow up assessment
|
The investigators will assess the number of participants who withdraw or stay within the study.
|
Will be evaluated after the 12-month follow up assessment
|
|
Adherence to the prescribed exercise sessions.
Time Frame: Will be evaluated after the 12-month follow up assessment.
|
The investigators will collect exercise session data recorded by the Polar Ignite watches worn by the participants in the intervention arm.
The percentage of prescribed exercise sessions completed will be assessed.
|
Will be evaluated after the 12-month follow up assessment.
|
|
Adherence to the prescribed exercise sessions' intensity.
Time Frame: Will be evaluated after the 12-month follow up assessment.
|
The investigators will collect exercise session data recorded by the Polar Ignite watches worn by the participants in the intervention arm.
The percentage of exercise time completed at the correct intensity will be assessed.
|
Will be evaluated after the 12-month follow up assessment.
|
|
Adherence to the prescribed exercise sessions' duration.
Time Frame: Will be evaluated after the 12-month follow up assessment.
|
The investigators will collect exercise session data recorded by the Polar Ignite watches worn by the participants in the intervention arm.
The percentage of exercise time completed at the correct duration will be assessed.
|
Will be evaluated after the 12-month follow up assessment.
|
|
Trial acceptability of the interventions and trial procedures via participant interviews
Time Frame: Interviews at 3 months
|
Qualitative semi-structured interviews carried out with control and intervention participants as well as interviews with participants who withdraw from the study.
|
Interviews at 3 months
|
|
Trial acceptability of the interventions and trial procedures via participant interviews
Time Frame: Interviews at 6 months
|
Qualitative semi-structured interviews carried out with control and intervention participants as well as interviews with participants who withdraw from the study.
|
Interviews at 6 months
|
|
Trial acceptability of the interventions and trial procedures via participant interviews
Time Frame: Interviews at 12 months
|
Qualitative semi-structured interviews carried out with control and intervention participants as well as interviews with participants who withdraw from the study.
|
Interviews at 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Exercise capacity determined using an Incremental Shuttle Walk Test (ISWT).
Time Frame: Baseline, 3-, 6- and 12 month follow up post randomisation
|
To assess heart rate and rating of perceived exertion over a 15 meter shuttle walk.
Increases in distance walked indicates a higher exercise capacity.
Changes in distance walked will be compared to participants randomised to the intervention vs the control group over time.
|
Baseline, 3-, 6- and 12 month follow up post randomisation
|
|
Physical activity and sedentary behaviour
Time Frame: The Actigraph will be worn during the baseline assessment and the 3-, 6, and 12-month follow up post randomisation.
|
Using an Actigraph to measure free-living sedentary behaviour and physical activity behaviour.
Changes in physical activity and sedentary behaviour will be compared to participants randomised to the intervention vs the control group over time.
|
The Actigraph will be worn during the baseline assessment and the 3-, 6, and 12-month follow up post randomisation.
|
|
Exercise frequency and intensity
Time Frame: It will be completed monthly from baseline to the 12-month follow up period to assess change over time.
|
The Godin Leisure Time Exercise Questionnaire will be completed monthly to assess the frequency of 3 different exercise intensities over a week.
Changes in exercise frequency and intensity will be compared to participants randomised to the intervention vs the control group over time.
The questionnaire is broken down into strenuous, moderate, and mild physical activity completed in bouts of 15 minutes or more over the last week.
A higher score indicates a more active individual and a lower score indicates a less active individual.
|
It will be completed monthly from baseline to the 12-month follow up period to assess change over time.
|
|
Cardiovascular disease risk using the Second Manifestations of Arterial disease (SMART) risk score
Time Frame: Measured at baseline, 3-, 6- and 12-month follow up
|
A score taking into account cardiovascular history, smoking, blood pressure, and measures from blood samples including a full lipid profile, estimated glomerular filtration rate and high-sensitivity C-reactive protein.
It identifies patients at a high risk of a reoccurring vascular event within 10 years.
Changes in the risk score will be compared to participants randomised to the intervention vs the control group over time.
|
Measured at baseline, 3-, 6- and 12-month follow up
|
|
Cardiac specific quality of life using the MacNew Quality of Life Questionnaire
Time Frame: Baseline, 3-, 6-, and 12-months post randomisation.
|
Using the MacNew Quality of Life Questionnaire to assess health-related quality of life. 1 indicates low health-related quality of life and 7 indicates high quality of life.
Scores will be compared between participants randomised to the intervention vs the control group over time.
|
Baseline, 3-, 6-, and 12-months post randomisation.
|
|
Depression using the Patient Health Questionnaire (PHQ-9)
Time Frame: Baseline, 3-, 6-, and 12-months post randomisation.
|
Scores represent mild (0-5, moderate (6-10), moderately severe (11-15) and severe depression (16-20).
Scores will be compared between participants randomised to the intervention vs the control group over time.
|
Baseline, 3-, 6-, and 12-months post randomisation.
|
|
Anxiety using the Generalised Anxiety Disorder 7-item Scale (GAD-7)
Time Frame: Baseline, 3-, 6-, and 12-months post randomisation.
|
A self report questionnaire to measure generalised anxiety disorder.
Scores represent mild (0-5), moderate (6-10), moderately severe anxiety (11-15), and severe anxiety (15-21).
Scores will be compared between participants randomised to the intervention vs the control group over time.
|
Baseline, 3-, 6-, and 12-months post randomisation.
|
|
Self efficacy using the General Self-Efficacy Scale (GSE)
Time Frame: Baseline, 3-, 6-, and 12-months post randomisation.
|
A 10-item psychometric scale to assess optimistic self-beliefs to cope with a range of life demands.
Total scores can range from 10 up to 40.
A higher score indicates a higher level of self-efficacy.
Scores will be compared between participants randomised to the intervention vs the control group over time.
|
Baseline, 3-, 6-, and 12-months post randomisation.
|
|
Patient activation using the Patient Activation Measure
Time Frame: Baseline, 3-, 6-, and 12-months post randomisation.
|
Higher levels of activation are linked to positive health behaviours and outcomes.
Scores will be compared between participants randomised to the intervention vs the control group over time.
|
Baseline, 3-, 6-, and 12-months post randomisation.
|
|
Health utility using the EQ-5D-5L
Time Frame: Baseline, 3-, 6-, and 12-months post randomisation.
|
The responses to the questionnaire can be converted into a health utility score using 5 levels to define a health state.
Scores will be compared between participants randomised to the intervention vs the control group over time.
|
Baseline, 3-, 6-, and 12-months post randomisation.
|
|
Health and social care resource use using the Client Service Receipt Inventory (CSRI)
Time Frame: Baseline, 3-, 6-, and 12-months post randomisation.
|
We will use a health and social care resource use questionnaire to examine the feasibility of collecting these data and refine resource use schedules for use in a definitive trial.
We will also test the feasibility of collecting patient-reported health outcome data.
Scores will be compared between participants randomised to the intervention vs the control group over time.
|
Baseline, 3-, 6-, and 12-months post randomisation.
|
|
Cost of the study
Time Frame: Baseline, 3-, 6-, and 12-months post randomisation.
|
Cost of staff, the facility, consumables etc. of delivering active and control interventions.
Costs will be compared between participants randomised to the intervention vs the control group.
|
Baseline, 3-, 6-, and 12-months post randomisation.
|
|
Safety assessed via adverse and serious adverse events
Time Frame: Baseline, 3-, 6-, and 12-months post randomisation.
|
Events will be documented in accordance with Good Clinical Practice (GCP).
Adverse and serious adverse events will be compared between participants randomised to the intervention vs the control group over time.
|
Baseline, 3-, 6-, and 12-months post randomisation.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Gordon McGregor, PhD, Coventry University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 28, 2022
Primary Completion (Actual)
February 15, 2024
Study Completion (Actual)
February 15, 2024
Study Registration Dates
First Submitted
December 16, 2021
First Submitted That Met QC Criteria
March 21, 2022
First Posted (Actual)
March 23, 2022
Study Record Updates
Last Update Posted (Actual)
August 20, 2024
Last Update Submitted That Met QC Criteria
August 19, 2024
Last Verified
August 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 302243
- 121990 (Other Identifier: Coventry University Ethics)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Heart Disease
-
Shenyang Northern HospitalRecruitingCoronary Heart Disease (CHD)China
-
Peking University Third HospitalCompletedCoronary Microvascular Dysfunction | Obstructive Coronary Heart DiseaseChina
-
Chang Gung University of Science and TechnologyChang Gung Memorial Hospital; Chang Gung University; National Science and Technology...Enrolling by invitationCoronary Heart Disease (CHD) | Coronary Arterial Disease (CAD)Taiwan
-
Deutsches Herzzentrum MuenchenCompletedCoronary Heart DiseaseGermany
-
Tung Wah CollegeRecruitingCoronary Heart Disease (CHD)Hong Kong
-
China National Center for Cardiovascular DiseasesChinese Academy of Medical Sciences, Fuwai HospitalNot yet recruiting
-
Tsinghua UniversityNot yet recruitingCoronary Heart Disease (CHD)
-
MedImmune LLCCompletedStable Coronary Heart DiseaseUnited States
-
Medical University of LodzBaxter Healthcare CorporationUnknownCHD - Coronary Heart DiseasePoland
-
University of ZurichCompletedStable Coronary Heart DiseaseSwitzerland
Clinical Trials on Polar Ignite Wearable Activity Monitor
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Medical Research Council; Liverpool... and other collaboratorsRecruitingDiabetes Mellitus, Type 2 | Telemedicine | Mobile Applications | Exercise TherapyCanada
-
Cedars-Sinai Medical CenterUnited States Department of DefenseActive, not recruitingProstate CancerUnited States
-
Cedars-Sinai Medical CenterActive, not recruitingNeoplasms | Cancer | Cancer, MetastaticUnited States
-
University of CincinnatiCompletedPulmonary Arterial HypertensionUnited States
-
University Health Network, TorontoUniversity of TorontoCompletedBreast Cancer | Fatigue | Physical Activity | Prostate Cancer | Sedentary BehaviourCanada
-
Boston Scientific CorporationCompletedOrthostatic Hypotension | Reflex SyncopeUnited States
-
Boston Scientific CorporationTerminatedHeart Failure NYHA Class II | Heart Failure NYHA Class III | Insertable Cardiac MonitorUnited States
-
Ann-Marie RoslandNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); The...Enrolling by invitationType 2 Diabetes Mellitus (T2DM)United States
-
University of TurkuAcademy of Finland; Juho Vainio Foundation; Ministry of Education and Culture...CompletedExercise | Aging | RetirementFinland
-
Boston Scientific CorporationNot yet recruitingOrthostatic Hypotension | Reflex SyncopeUnited States